Literature DB >> 12695288

Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.

John Kao1, Jon Kobashigawa, Michael C Fishbein, W Robb MacLellan, Marie D Burdick, John A Belperio, Robert M Strieter.   

Abstract

BACKGROUND: Human and animal studies of acute allograft rejection have implicated CCR5 and CXCR3 chemokines as causative factors. However these chemokines have not been assessed in transplant coronary artery disease (TCAD). METHODS AND
RESULTS: Serum levels of chemokines were measured by ELISA. Levels of ITAC/CXCL11 were found to be elevated in patients with severe TCAD compared with long-term survivors of transplantation without TCAD and with healthy volunteers who had not undergone transplantation (1.476+/-0.274 ng/mL, 0.926+/-0.466 ng/mL, and 0.741+/-0.321 ng/mL, respectively; P<0.05 for all comparisons to TCAD group). Immunohistochemical localization confirmed the presence of CXCR3+ mononuclear cells within lesions and the presence of the ligand, ITAC/CXCL11, on the surface of endothelial cells associated with TCAD.
CONCLUSIONS: Elevated peripheral blood levels of the CXCR3 chemokine ITAC/CXCL11 are associated with severe TCAD and may serve as a marker for patients at increased risk for the development of this disease. Immunohistochemical localization of the CXCR3 chemokine ligand ITAC/CXCL11 on the endothelial surface of TCAD lesions with underlying infiltration of inflammatory mononuclear cells expressing CXCR3 suggests a causative role for this chemokine in the development of TCAD. The present study is one of the first to demonstrate a role for ITAC/CXCL11 in this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695288     DOI: 10.1161/01.CIR.0000069270.16498.75

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease.

Authors:  Mi Jeong Kim; Roberto Romero; Chong Jai Kim; Adi L Tarca; Sovantha Chhauy; Christopher LaJeunesse; Deug-Chan Lee; Sorin Draghici; Francesca Gotsch; Juan Pedro Kusanovic; Sonia S Hassan; Jung-Sun Kim
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

2.  Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Authors:  D J Scholten; M Canals; M Wijtmans; S de Munnik; P Nguyen; D Verzijl; I J P de Esch; H F Vischer; M J Smit; R Leurs
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

4.  Oscillatory mTOR inhibition and Treg increase in kidney transplantation.

Authors:  M Sabbatini; G Ruggiero; A T Palatucci; V Rubino; S Federico; A Giovazzino; L Apicella; M Santopaolo; G Matarese; M Galgani; G Terrazzano
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

5.  Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.

Authors:  Aric L Gregson; Aki Hoji; Vyacheslav Palchevskiy; Scott Hu; S Samuel Weigt; Eileen Liao; Ariss Derhovanessian; Rajeev Saggar; Sophie Song; Robert Elashoff; Otto O Yang; John A Belperio
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

6.  CC chemokine receptor-1 activates intimal smooth muscle-like cells in graft arterial disease.

Authors:  Koichi Shimizu; Manabu Minami; Rica Shubiki; Marco Lopez-Ilasaca; Lindsey MacFarlane; Yukiko Asami; Yuxin Li; Richard N Mitchell; Peter Libby
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

Review 7.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

8.  Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.

Authors:  S S Weigt; R M Elashoff; M P Keane; R M Strieter; B N Gomperts; Y Y Xue; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; D J Ross; J P Lynch; D A Zisman; J A Belperio
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

9.  Mapping Transplant Arteriosclerosis Cell-by-Cell: A Path to New Immune Insights.

Authors:  Dawn M Fernandez; Chiara Giannarelli
Journal:  Circ Res       Date:  2020-09-24       Impact factor: 17.367

Review 10.  Chemokines and transplant vasculopathy.

Authors:  John A Belperio; Abbas Ardehali
Journal:  Circ Res       Date:  2008-08-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.